These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19731929)

  • 1. Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.
    Wilbur DS; Thakar MS; Hamlin DK; Santos EB; Chyan MK; Nakamae H; Pagel JM; Press OW; Sandmaier BM
    Bioconjug Chem; 2009 Oct; 20(10):1983-91. PubMed ID: 19731929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
    Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.
    Wilbur DS; Chyan MK; Hamlin DK; Nguyen H; Vessella RL
    Bioconjug Chem; 2011 Jun; 22(6):1089-102. PubMed ID: 21513347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.
    Wilbur DS; Chyan MK; Hamlin DK; Perry MA
    Bioconjug Chem; 2009 Mar; 20(3):591-602. PubMed ID: 19236022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.
    Wilbur DS; Chyan MK; Nakamae H; Chen Y; Hamlin DK; Santos EB; Kornblit BT; Sandmaier BM
    Bioconjug Chem; 2012 Mar; 23(3):409-20. PubMed ID: 22296587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
    Nakamae H; Wilbur DS; Hamlin DK; Thakar MS; Santos EB; Fisher DR; Kenoyer AL; Pagel JM; Press OW; Storb R; Sandmaier BM
    Cancer Res; 2009 Mar; 69(6):2408-15. PubMed ID: 19244101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
    Wilbur DS; Hamlin DK; Chyan MK; Brechbiel MW
    Bioconjug Chem; 2008 Jan; 19(1):158-70. PubMed ID: 18072725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.
    Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Risler R; Pathare PM; Quinn J; Vessella RL; Foulon C; Zalutsky M; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2004; 15(1):203-23. PubMed ID: 14733601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.
    Li Y; Chyan MK; Hamlin DK; Nguyen H; Vessella R; Wilbur DS
    Nucl Med Biol; 2021 Jan; 92():217-227. PubMed ID: 32409263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Labeling Monoclonal Antibody with α-emitting
    Vaidyanathan G; Pozzi OR; Choi J; Zhao XG; Murphy S; Zalutsky MR
    Cancer Biother Radiopharm; 2020 Sep; 35(7):511-519. PubMed ID: 32109139
    [No Abstract]   [Full Text] [Related]  

  • 11. Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.
    Wilbur DS; Chyan MK; Hamlin DK; Perry MA
    Nucl Med Biol; 2010 Feb; 37(2):167-78. PubMed ID: 20152716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts.
    Safavy A; Khazaeli MB; Safavy K; Mayo MS; Buchsbaum DJ
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
    Orozco JJ; Balkin ER; Gooley TA; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Hylarides MD; Shadman M; Green DJ; Gopal AK; Press OW; Pagel JM
    PLoS One; 2014; 9(12):e113601. PubMed ID: 25460570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.
    Frost SH; Miller BW; Bäck TA; Santos EB; Hamlin DK; Knoblaugh SE; Frayo SL; Kenoyer AL; Storb R; Press OW; Wilbur DS; Pagel JM; Sandmaier BM
    J Nucl Med; 2015 Nov; 56(11):1766-73. PubMed ID: 26338894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies.
    Li Y; Hamlin DK; Chyan MK; Wong R; Dorman EF; Emery RC; Woodle DR; Manger RL; Nartea M; Kenoyer AL; Orozco JJ; Green DJ; Press OW; Storb R; Sandmaier BM; Wilbur DS
    PLoS One; 2018; 13(10):e0205135. PubMed ID: 30335787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
    Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
    J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.
    Talanov VS; Yordanov AT; Garmestani K; Milenic DE; Arora HC; Plascjak PS; Eckelman WC; Waldmann TA; Brechbiel MW
    Nucl Med Biol; 2004 Nov; 31(8):1061-71. PubMed ID: 15607488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.
    Wilbur DS; Hamlin DK; Chyan MK; Kegley BB; Quinn J; Vessella RL
    Bioconjug Chem; 2004; 15(3):601-16. PubMed ID: 15149189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.
    Chen Y; Kornblit B; Hamlin DK; Sale GE; Santos EB; Wilbur DS; Storer BE; Storb R; Sandmaier BM
    Blood; 2012 Feb; 119(5):1130-8. PubMed ID: 22134165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.